Session 6 WEBVTT

9 00:17:14.550 --> 00:17:15.390 Kim Kelly: Can you folks hear me?

10

00:17:17.520 --> 00:17:26.790 Kim Kelly: Okay sorry for the delay, I wasn't able to get in. I was having a little trouble and calling around so I'm appreciative for the

11 00:17:28.290 --> 00:17:34.110 Kim Kelly: folks that are working with us and getting things set up so

12

00:17:36.510 --> 00:17:40.140 Kim Kelly: I apologize for the delay, and I thank you for your patience.

13

00:17:41.400 --> 00:17:43.560 Kim Kelly: So if we're ready, I believe we're

14 00:17:43.560 --> 00:17:44.250 Kim Kelly: recording.

15 00:17:45.090 --> 00:17:46.350 Kim Kelly: Are we recording now?

16 00:17:48.210 --> 00:17:50.010 wade bowser: Yes, ma'am.

17 00:17:50.940 --> 00:17:51.420 Kim Kelly: Thank you. Alright.

18 00:17:52.980 --> 00:17:56.400 Kim Kelly: So I was getting in on two different computers, so that we could

19

00:17:58.530 --> 00:18:01.440 Kim Kelly: I can, I can make sure that I was there all right.

20 00:18:03.660 --> 00:18:04.470 Kim Kelly: You just leave this

21

00:18:07.980 --> 00:18:28.320

Kim Kelly: screen. So welcome everyone to the sixth session of the webinar series on Genetic Services in Appalachia. We ask that you mute your microphone for the talk and place any comments or questions in the chat box, and we should have time to ask some questions towards the end.

22

00:18:31.080 --> 00:18:48.000

Kim Kelly: At the end of the session today, we will ask you to complete an assessment to give us feedback. As you know, our aims include to develop a research agenda for genetic services in rural Appalachia. Each month we've been having speakers who are working in genetic service provision

23

00:18:48.210 --> 00:19:01.350

Kim Kelly: to the medically underserved populations around our area, with a focus on setting a research agenda in rural Appalachia. I would now like to introduce our speaker.

25

00:19:05.550 --> 00:19:12.000

Kim Kelly: And I'll just ask everyone to mute their microphones, please give it a double check.

26

00:19:13.260 --> 00:19:24.540

Kim Kelly: Dr. Graves received her PhD in clinical psychology from Virginia Polytechnic Institute and State University and completed postdoctoral training at the University of Kentucky.

27

00:19:25.680 --> 00:19:32.310 Kim Kelly: She is a tenured Associate Professor of Oncology in the Cancer Prevention and Control Program.

28

00:19:33.060 --> 00:19:42.480 Kim Kelly: In January 2021, Dr. Graves began serving as the Associate Dean for Faculty Development at Georgetown University Medical Center.

29

00:19:43.260 --> 00:19:53.220

Kim Kelly: Her research focuses on cancer survivorship and translational genomics with a particular emphasis on community engagement and addressing health disparities.

30

00:19:53.610 --> 00:20:03.690

Kim Kelly: Dr. Graves is co-leading an R01 funded project to explore symptoms experienced by patients diagnosed with thyroid cancer, who receive radioactive iodine treatment.

31

00:20:04.590 --> 00:20:13.650

Kim Kelly: She is site PI on an R01 to evaluate an expressive helping writing intervention to reduce symptoms among patients treated with stem cell transplant.

32

00:20:14.160 --> 00:20:24.360

Kim Kelly: Another area in which Dr. Graves conducts work is raising awareness about genetic counseling and testing and underserved communities, which is what is going to be the focus of her talk today.

00:20:25.050 --> 00:20:36.630

Kim Kelly: She is a multiple principal investigator on an NCI-R25 award to train Community health educators, patient navigators, and promotoras

34

00:20:37.080 --> 00:20:48.240

Kim Kelly: about hereditary breast and ovarian cancer and Latinos. This training project is called ARBOLES Familiares (Family Tree).

35

00:20:48.930 --> 00:21:04.530

Kim Kelly: And so I also know that Dr. Grave's has done a fair bit of work with the Appalachian population in Kentucky; so we look forward to hearing her presentation today. Are you ready Dr. Graves to share your screen?

36

00:21:05.520 --> 00:21:11.070

Kristi Graves: Thank you so much, Dr. Kelly; I'm really excited to be here. Yes, I can share my screen, thank you.

37

00:21:15.510 --> 00:21:17.370 Kristi Graves: Can everyone see that okay?

38

00:21:20.010 --> 00:21:28.860

Kristi Graves: Great alright. Well I'm really excited to be with you all today, and we should have plenty of time at the end for questions and answers.

39

00:21:30.840 --> 00:21:49.860

Kristi Graves: So no formal disclosures. This was taken when we were at our most recent ARBOLES Familiares training, which was last November. Our first in-person training in two years, and we had a guest who like to watch and learn about genetics standing outside.

40

00:21:52.200 --> 00:22:06.030

Kristi Graves: So many of you may be familiar with this translational continuum, but I want to just to set the stage for us today to think about how some of the basic science genetics work and the discovery of the

41

00:22:06.720 --> 00:22:28.410

Kristi Graves: genes related to hereditary cancer is now moving, you know, not only well into practice, but also through ways that we can then bring these discoveries into the community, and ideally, take ideas and lessons from the community to inform the research and how we deliver this care.

42

00:22:32.850 --> 00:22:52.650

Kristi Graves: A reminder I'm sure for this group, but just to put the context that again, about 10% of colorectal cancers and breast cancers are considered hereditary with a larger proportion of individuals who are diagnosed with ovarian cancer having hereditary cancer.

00:22:55.380 --> 00:23:01.380 Kristi Graves: And again likely a review for this group, but just to reinforce some of the potential impacts

44

00:23:01.770 --> 00:23:16.170

Kristi Graves: that someone may have, if they do have genetic counseling, opt for genetic testing, and then receive a positive genetic test result, so it could influence someone's patterns of their cancer screening.

45

00:23:17.100 --> 00:23:31.410

Kristi Graves: In terms of either frequency or type of screening, for individuals who are found to have positive test results, it might reduce, it might influence uptake of risk reducing surgery, for example, prophylactic oophorectomy.

46

00:23:32.700 --> 00:23:40.680

Kristi Graves: It might influence in a small number, and we know that this research is growing, but to think about chemo prevention

47

00:23:41.520 --> 00:23:47.940

Kristi Graves: through use of selective estrogen receptor modulators or aromatase inhibitors.

48

00:23:48.900 --> 00:23:58.740

Kristi Graves: For some, it might influence how they think about their lifestyle, for example, reducing alcohol intake to also reduce the risk of breast cancer.

49

00:23:59.490 --> 00:24:08.970

Kristi Graves: For individuals who have been diagnosed with cancer and then have a positive test result, it could influence the type of chemotherapy that their

50

00:24:09.480 --> 00:24:24.330

Kristi Graves: provider team recommends or the again the type of treatment, for example, a woman diagnosed with a unilateral breast cancer, who have who has a positive test result may decide to have contralateral prophylactic mastectomy, on the other, breast

51

00:24:25.500 --> 00:24:41.760

Kristi Graves: to reduce risk of cancer and that risk. And then of course implications for family members, the idea that others may carry this gene and may find it useful to have genetic counseling and perhaps genetic testing.

52

00:24:45.420 --> 00:24:50.340

Kristi Graves: So I wanted to set the stage for what we're going to talk about with

53

00:24:51.360 --> 00:24:58.200

Kristi Graves: genetic services and finding ways to reduce barriers of uptake by reminding us that

00:24:59.340 --> 00:25:15.720

Kristi Graves: the uptake of genetic testing does remain lower than it could be, both in individuals who are affected with breast cancer and among individuals who are affected with ovarian cancer, and these are some studies from 2019.

55

00:25:19.770 --> 00:25:28.020

Kristi Graves: And so soon after I arrived at Georgetown, one of the projects that I had the opportunity to work on, and this is when I was

56

00:25:30.300 --> 00:25:39.120

Kristi Graves: project director as an instructor so I was really fortunate to be able to enter into this study, which was a

57

00:25:40.200 --> 00:25:57.540

Kristi Graves: non-inferiority study, where two different approaches to genetic counseling were evaluated. And so the overall goal of this project, we called it, the telephone genetic counseling study or TGC,

58

00:25:58.860 --> 00:26:10.620

Kristi Graves: was to look at, and this was back in you know early 2009 and 10 when we were looking at this, is there equivalence between

59

00:26:11.640 --> 00:26:17.370

Kristi Graves: genetic counseling that's done over the telephone and genetic counseling that's done inperson?

60

00:26:18.750 --> 00:26:25.860 Kristi Graves: This question I think has been answered, more recently, as well, but this was one of the first studies to do a full

61

00:26:26.580 --> 00:26:37.890

Kristi Graves: equivalence type study of these two approaches. And so the goal, and this work was led by my mentor Mark Schwartz, but at the time it was to compare the safety,

62

00:26:38.430 --> 00:26:46.590 Kristi Graves: are we causing any harm, if we're not having a patient sit directly in front of us, the efficacy, does it work as well.

63

00:26:47.250 --> 00:26:52.740 Kristi Graves: When genetic counseling is delivered over the telephone in terms of patients understanding.

64

00:26:53.490 --> 00:27:10.890

Kristi Graves: If they have any distress, the types of decisions they make about genetic testing, and then another component I won't be presenting today but it's in the paper referred here, is the cost. The take home message, there is that telephone genetic counseling costs less than in person.

65

00:27:12.330 --> 00:27:32.790

Kristi Graves: So again, this was a non-inferiority trial we recruited women from four different sites, you can see some of the reasons why people declined or we're not fully enrolled in the study and then randomize to telephone counseling or usual care in person counseling.

66

00:27:34.620 --> 00:27:45.990

Kristi Graves: And we compared to the outcomes two weeks after the genetic counseling and then again following receipt of the genetic test for those who are interested in having testing.

67

00:27:47.700 --> 00:27:58.260

Kristi Graves: So the take home messages here, we did not see any differences in uptake of genetic counseling when people were offered to do the genetic counseling either in person

68

00:27:58.680 --> 00:28:11.490

Kristi Graves: or by telephone. So it was equally accessible and appealing to folks. We did see a slight decrease in the uptake of genetic testing

69

00:28:12.150 --> 00:28:27.630

Kristi Graves: for those who were randomized to telephone genetic counseling or telegenetics. So 90% of those who were in person with their genetic counseling had opted for genetic testing versus 84% and

70

00:28:28.200 --> 00:28:42.480

Kristi Graves: we can talk about this again at the end. One of the big differences was that when someone's in front of you in in in the center, they can walk immediately to the at that time, the blood draw room

71 00:28:43.710 --> 00:28:47.670 Kristi Graves: to have a sample taken for genetic testing.

72

00:28:48.750 --> 00:28:50.880 Kristi Graves: But with telegenetics it involved

73

00:28:51.990 --> 00:28:54.750 Kristi Graves: a kit to obtain a sample.

74

00:28:56.010 --> 00:28:59.280 Kristi Graves: If everybody could again check their mute that would be great.

75

00:29:04.170 --> 00:29:06.630

Kristi Graves: So, then the other piece was the

76

00:29:08.310 --> 00:29:16.170

Kristi Graves: efficacy. Do we see the same results across these two modes of delivery of genetic counseling and this

77

00:29:16.620 --> 00:29:25.530

Kristi Graves: time point was after genetic, the first genetic counseling session, but before disclosure of the genetic testing results.

78

00:29:26.070 --> 00:29:44.160

Kristi Graves: And the yellow framing on the graph to the right indicate the range, at which the scores would be considered non-inferior meaning no differences in this non-inferiority trial. So because the

79

00:29:44.820 --> 00:29:58.740

Kristi Graves: confidence limit does not extend past the yellow range, it was found that telephone genetic counseling was not inferior to in person genetic counseling on

80

00:29:59.100 --> 00:30:15.630

Kristi Graves: patient satisfaction with the process their knowledge about what it means to have a hereditary cancer syndrome or be at risk for hereditary cancer syndrome, their perceived stress overall kind of global stress, as well as cancer distress.

81

00:30:18.330 --> 00:30:29.700

Kristi Graves: Then we looked at similar outcomes after the disclosure of test results, because you know there potentially could be differences, if someone

82

00:30:30.630 --> 00:30:37.380

Kristi Graves: you know, was able to have genetic testing and then how they understood that information or or how it made them feel.

83

00:30:37.740 --> 00:30:49.260

Kristi Graves: Once they got their test results so again, it was found that telephone genetic counseling or telegenetic counseling was not inferior to in person genetic counseling on all of the

84

00:30:49.560 --> 00:31:04.200

Kristi Graves: key outcomes that were assessed in terms of physical functioning, mental functioning that was assessed with a kind of global quality of life type index. Perceived stress, cancer distress. and importantly decisional conflict.

85

00:31:05.250 --> 00:31:15.600

Kristi Graves: Individuals who had the telephone genetic counseling did not experience more conflict about their decisions to have genetic testing and those who had in-person.

00:31:18.000 --> 00:31:23.250 Kristi Graves: And so from those results, we were interested in

87

00:31:24.300 --> 00:31:34.650

Kristi Graves: you know, as time went on, and we learned more about genetics and genetic risk we were interested in extending some of this work to other types of cancers, as well as

88

00:31:35.430 --> 00:31:53.280

Kristi Graves: different levels of risk conveyed, and so I led a pilot study to look at individuals who were identified from primary care clinics for interest and uptake of testing for a single nucleotide polymorphism.

89

00:31:54.390 --> 00:32:10.230

Kristi Graves: related to colon cancer risk. And so we wanted to know who might be interested in this type of testing what information is important to make sure that people understand the information and then importantly, how we should communicate this information to diverse audiences.

90

00:32:11.430 --> 00:32:16.350

Kristi Graves: And so the the protocol was that we would recruit from primary care.

91

00:32:17.400 --> 00:32:36.180

Kristi Graves: And, given the at the time, relative novelty of looking at single nucleotide polymorphism, we thought it was best to stick with the in person genetic counseling for this project but we've since looked at other ways of delivering information,

92

00:32:37.230 --> 00:32:46.260

Kristi Graves: by telephone. Individuals could choose whether to have or not a SNP test and then after the test results were returned,

93 00:32:48.210 --> 00:32:51.600 Kristi Graves: coming in to discuss the results.

94

00:32:54.960 --> 00:32:56.130 Kristi Graves: And so we worked

95

00:32:57.540 --> 00:33:14.370

Kristi Graves: hard to find ways to communicate this risk, and now, when I look at this, you know, many years later, it seems even more complicated than it should have been. At the time we were we were working to follow best practices and risk communication and so describing what the SNPs we're

96

00:33:15.510 --> 00:33:22.440 Kristi Graves: conveying, the level of increased risk, by showing someone what increased risk look like versus not increased risk.

00:33:22.710 --> 00:33:35.970

Kristi Graves: Placing that in the context of of the grid, with the number of people highlighted, in terms of estimated lifetime risk of colon cancer, based on the on the genetics, the genomic profile.

98

00:33:37.050 --> 00:33:47.520

Kristi Graves: Also at the time, we wanted to make sure that people knew that this was you know not conclusive; it was still in the research phase that it was based on only three specific SNPs.

99

00:33:48.660 --> 00:33:55.050

Kristi Graves: That we didn't know how other types of colon cancer risk factors related with these SNPs as well as

100

00:33:55.800 --> 00:34:11.070

Kristi Graves: the limited evidence on this estimates for individuals who are not from predominantly European descent, given how some of the studies and the risk estimates were were concluded at the time.

101

00:34:15.030 --> 00:34:17.070 Kristi Graves: And so we found strong

102

00:34:17.100 --> 00:34:28.410

Kristi Graves: interest overall in this type of genomic testing for colorectal cancer risk, and this again, small pilot study, of individuals recruited from primary care so.

103

00:34:29.430 --> 00:34:31.530 Kristi Graves: not pre-selected for any

104

00:34:31.530 --> 00:34:45.600

Kristi Graves: types of risk factors for colon cancer, although they did have a range of different types of risk factors both familial risk, as well as behavioral risk factors, so we wanted to know you know, do people

105

00:34:46.350 --> 00:34:57.690

Kristi Graves: change their behavior based on this risk information, because it was a shorter term follow up with three months, we assessed intentions for colorectal cancer screening.

106

00:34:59.190 --> 00:35:08.820

Kristi Graves: And then looked at reports of physical activity and healthy eating. And we did see that there were some changes in terms of

107

00:35:10.140 --> 00:35:25.410

Kristi Graves: individuals noting that they were going to communicate with their physician about colon cancer risk factors and colon cancer screening. A quarter of them had made an appointment for colorectal cancer screening and

00:35:26.670 --> 00:35:38.970

Kristi Graves: again intent, we know intentions, don't always predict behavior, but we were pleased to see that 100% of the individuals who are due for colorectal cancer screening intended to have one.

109

00:35:44.130 --> 00:35:51.060

Kristi Graves: So I mentioned earlier, we were interested in and learning about how we communicate this level of of genomic risk

110

00:35:51.630 --> 00:36:13.500

Kristi Graves: to patients, and so I was really fortunate to have a number of genetic counselors on the team. And we audio recorded the disclosure sessions that we had with participants, and then we did a discourse analysis of those genetic counseling transcripts and Morgan Butrick

111

00:36:14.790 --> 00:36:24.150

Kristi Graves: had had some experience she had worked at the National Cancer Institute as a genetic counseling fellow and she had had some experience with coding

112

00:36:24.570 --> 00:36:48.210

Kristi Graves: these transcripts in terms of labeling verbal dominance, as well as turn-taking and used a specific coding program called Reas to do that, and so we did find that genetic counselors demonstrated greater levels of verbal dominance with patients who were

113

00:36:50.040 --> 00:36:58.140

Kristi Graves: underrepresented, and a lot of genetic studies so black and African American patients, Latino patients, so I think

114

00:36:58.470 --> 00:37:13.680

Kristi Graves: taking something like this could be interesting to look at other types of populations, rural populations and the like, is you know, do we have similar rates of verbal dominance of genetic counselors with different types of patients.

115

00:37:14.730 --> 00:37:29.520

Kristi Graves: And we looked as I mentioned before we gave a caveat to our participants about the interpretation of some of the data based on the limited, at the time, the limited findings for risk estimates

116

00:37:30.270 --> 00:37:38.220

Kristi Graves: based on the Genome Wide Association Study estimates that we had, whereas most of those estimates were based on European

117

00:37:39.300 --> 00:37:48.450

Kristi Graves: descent populations, and so there were some differences in terms of some of the process outcomes again by participant's race.

00:37:49.170 --> 00:37:58.260

Kristi Graves: In terms of coverage of the topics that we had in our educational materials, the booklets that you saw a snapshot of previously and then

119

00:37:59.160 --> 00:38:11.580

Kristi Graves: the genetic counselors ability to adequately assess participants understanding of the information and in the bubble, there are some quote extracts from our transcripts.

120

00:38:12.870 --> 00:38:20.610

Kristi Graves: This was some of the earlier work, there's been some really intriguing work by others in the field, looking at unconscious bias, not only in

121

00:38:21.090 --> 00:38:37.800

Kristi Graves: genetic counselors, but this has been applied across a lot of different healthcare professionals and we all carry around these biases and so thinking about ways that we can recognize our patterns of communication with different populations could be, could be important.

122

00:38:40.500 --> 00:38:49.080

Kristi Graves: So, given some of that work and some of my survivorship work that had been in Latinx communities and specifically Latina

123

00:38:50.010 --> 00:39:04.410

Kristi Graves: women diagnosed with breast cancer, we were interested in taking some of this work and seeing what Latina women knew about hereditary breast and ovarian cancer and

124

00:39:05.490 --> 00:39:14.790 Kristi Graves: ways to make connections between genetic services and different types of populations in the community. And you know some of the

125

00:39:15.360 --> 00:39:24.720 Kristi Graves: legacy studies, looking at differences and awareness about hereditary breast and ovarian cancer by race and ethnicity.

126

00:39:25.680 --> 00:39:35.790 Kristi Graves: But then other work saying that once someone found out about the availability of genetic services, there was high level of interest.

127

00:39:36.660 --> 00:39:43.530 Kristi Graves: So we did some background formative work, this was led by a medical student who was interested in

128 00:39:44.310 --> 00:40:04.020 Kristi Graves: understanding from the perception of patients and community based members, so we collaborated with a community based organization, here in Washington D.C. and identified women who had had genetic risk factors in terms of strong family history or

129

00:40:05.100 --> 00:40:16.440

Kristi Graves: young age, at the time of diagnosis or diagnosis of ovarian cancer, and we found that our participants had a generally low awareness of hereditary breast and ovarian cancer.

130

00:40:17.370 --> 00:40:23.460

Kristi Graves: Some had never heard of genetic counseling, and many had never heard of genetic testing.

131

00:40:24.270 --> 00:40:33.660

Kristi Graves: Once the concepts of genetic counseling and genetic testing were explained, and this mentee created a fantastic short five-minute video in

132

00:40:34.470 --> 00:40:44.580

Kristi Graves: Spanish with English subtitles explaining kind of Genetics 101, what is hereditary breast and ovarian cancer, what is genetic counseling, what is genetic testing.

133

00:40:45.090 --> 00:40:55.320

Kristi Graves: Our participants indicated they were very interested in learning about this information, not only for themselves, but in particular for their family members.

134

00:40:56.640 --> 00:41:13.800

Kristi Graves: And a strong emphasis on value valuing health, although there were conversations about in that there's other competing priorities as well and wanting to take care of people and not always prioritizing making time for their own individual health.

135

00:41:14.940 --> 00:41:26.910

Kristi Graves: And then we also talked about and asked about barriers to genetic counseling and testing and the ones that kept surfacing included cost language barriers and insurance barriers.

136

00:41:30.480 --> 00:41:33.720

Kristi Graves: And so, based on this information and some others,

137

00:41:34.890 --> 00:41:41.850

Kristi Graves: formative work led by my collaborator Susan Vadaparampil, down at Moffitt Cancer Center. We set about

138

00:41:43.980 --> 00:42:02.490

Kristi Graves: developing a training program, and this is the one Dr. Kelly referred to that's called Árboles Familiares, or family tree in Spanish, and we wanted to help think through ways we could reduce barriers to accessing genetics professionals and genetic services

00:42:03.780 --> 00:42:17.790

Kristi Graves: which are often located in a you know, an urban center or in cities or in larger hospitals, when many people may receive their pair out in different community clinics.

140

00:42:19.170 --> 00:42:23.550

Kristi Graves: And so, our goal was to create this training program to

141

00:42:26.400 --> 00:42:36.840

Kristi Graves: develop a cohort of individuals who had high knowledge about hereditary breast and ovarian cancer confidence about how to explain cancer genetics

142

00:42:37.770 --> 00:42:52.380

Kristi Graves: in terms of talking with community members, and identify red flags for hereditary breast and ovarian cancer, so that they could make appropriate referrals and navigate women to fully trained genetics professionals.

143

00:42:56.040 --> 00:43:01.860

Kristi Graves: And so, our target training participants which we've abbreviated CORE-P.

144

00:43:03.930 --> 00:43:12.360

Kristi Graves: Just something we made up, but community health educators, Promotoras, lay health advisors or patient navigators.

145

00:43:13.980 --> 00:43:28.890

Kristi Graves: Sometimes these individuals who are working within the community are also called community health workers. Requirements for our training program or that they are bilingual in English and Spanish and engage with the Latino community.

146

00:43:30.000 --> 00:43:40.080 Kristi Graves: And we know from other work that individuals who are community health educators or community health workers have been very effective in improving cancer screening

147

00:43:40.590 --> 00:43:49.980

Kristi Graves: in different populations and that again they there was strong interest in building these bridges between genetics professionals and the community.

148

00:43:51.420 --> 00:43:57.300

Kristi Graves: And so here the goals of Árboles Familiares to increase trainees knowledge about genetics.

149

00:43:57.750 --> 00:44:13.170

Kristi Graves: Again, their understanding of what happens during genetic counseling and information about the genetic testing process and then build that self efficacy or their confidence in identifying individuals who are at high risk, and we have a two two format

150 00:44:14.310 --> 00:44:15.540 Kristi Graves: training plan

151

00:44:16.560 --> 00:44:23.880 Kristi Graves: that consists of in-person, workshops and online modules, although we during Covid, we had a completely virtual version.

152

00:44:27.420 --> 00:44:36.480

Kristi Graves: So individuals who are interested in the training program apply and complete a baseline survey, then we have two introductory modules, a very

153

00:44:36.900 --> 00:44:47.760 Kristi Graves: global overview of of Genetics 101 and Introduction to Hereditary Cancer, then we have our in-person workshop.

154

00:44:48.300 --> 00:45:00.480

Kristi Graves: And again, we were just able to redo this in November, for the first time in a while, but it's a two and a half day kind of intensive in person workshop that's followed by online learning modules.

155

00:45:01.770 --> 00:45:03.810 Kristi Graves: We ask that all of our trainees

156

00:45:04.950 --> 00:45:16.350

Kristi Graves: apply what they learn through what we call the action project and so that's application in the community that can be an educational session development of a navigation guide,

157

00:45:17.070 --> 00:45:31.320

Kristi Graves: development of a referral list to genetic specialists in their community. And then we've asked them, you know, how are things going, have you been able to educate women or individuals at risk for hereditary breast and ovarian cancer in the community?

158

00:45:32.610 --> 00:45:37.260

Kristi Graves: And, have you referred anyone? And we ask that at six months and 12 months.

159

00:45:39.540 --> 00:45:42.510

Kristi Graves: And throughout the next few slides there'll be some quotes

160 00:45:43.560 --> 00:45:46.200 Kristi Graves: on the slides that come from some of our trainees.

161

00:45:50.670 --> 00:46:00.090 Kristi Graves: So, in terms of the training itself, we have a variety of different learning methods again, the pictures you'll see our pre-covid

162

00:46:01.050 --> 00:46:13.650 Kristi Graves: you'll see some with post-covid with our masks on from November. But we have lectures and videos, a lot of small group discussion, we play games to help apply the information.

163 00:46:14.910 --> 00:46:17.430 Kristi Graves: We have role plays and mock sessions.

164

00:46:18.510 --> 00:46:26.430 Kristi Graves: And then different types of learning sessions, and we have made changes over the delivery of these different cohorts

165 00:46:27.240 --> 00:46:29.010 Kristi Graves: based on our participant and trainee

166 00:46:29.010 --> 00:46:29.700 Kristi Graves: feedback.

167 00:46:33.930 --> 00:46:38.700 Kristi Graves: In terms of the online training, we ask that participants

168

00:46:40.020 --> 00:46:50.160 Kristi Graves: do this every one to two weeks, we have a 30 minute recorded video lecture, they can also download the slides.

169

00:46:50.970 --> 00:47:02.130 Kristi Graves: And we asked them to complete a short evaluation after each one, and these are topics that focus on kind of the application of the information that they learned in the workshop and making it

170 00:47:03.450 --> 00:47:05.190 Kristi Graves: applicable to their community.

171 00:47:07.530 --> 00:47:08.880 Kristi Graves: So these include

172 00:47:10.110 --> 00:47:17.790 Kristi Graves: discussions about how to identify community members who are at risk, so reinforcing the identification of the red flags.

173

00:47:20.160 --> 00:47:28.110

Kristi Graves: As I mentioned, identifying local genetics professionals or services through existing web resources.

174

00:47:29.940 --> 00:47:31.860 Kristi Graves: and local hospitals and clinics.

175

00:47:33.300 --> 00:47:43.650

Kristi Graves: Identifying how they might go about providing referrals and navigation to those genetic services, creating community guides as an example of their training project.

176

00:47:44.430 --> 00:47:53.520

Kristi Graves: And we have both synchronous and asynchronous aspects, so that they could have questions answered or have a conversation with a genetic counselor.

177

00:47:57.690 --> 00:48:03.540

Kristi Graves: So far we have trained 179 individuals from different states.

178

00:48:05.430 --> 00:48:13.620

Kristi Graves: The project is housed in Washington DC, we have a partner site at Icahn School of Medicine in New York and then Moffitt Cancer Center

179

00:48:14.010 --> 00:48:30.090

Kristi Graves: in Florida. When we originally conceived of this idea we were thinking we would cover the East Coast, and you know a bit beyond the region, but we had interest from all over, not quite every state where that's one of our goals.

180

00:48:31.920 --> 00:48:50.460

Kristi Graves: But we did just host that our most recent training in California, because we have a partnership with the Latino Cancer Institute in California. You can see our trainees come from many different countries of origin, although they all are in the US, at the time of the training.

181

00:48:51.690 --> 00:49:02.160

Kristi Graves: And almost half identify as community health educators or patient navigators. We found that many of our trainees identified in in more than one role within their organization.

182

00:49:04.200 --> 00:49:08.550

Kristi Graves: In terms of demographics of our trainees, we most are women.

183

00:49:10.050 --> 00:49:15.330 Kristi Graves: We welcome men or individuals of non-binary gender to apply.

184 00:49:16.680 --> 00:49:17.550 Kristi Graves: In a

185

00:49:18.660 --> 00:49:27.930 Kristi Graves: different reported and identified races, largely our ethnicity is Hispanic given our focus on bilingual.

186 00:49:29.220 --> 00:49:33.930 Kristi Graves: And then differences across our trainees, in terms of language preference.

187

00:49:38.850 --> 00:49:42.630 Kristi Graves: To date, we've been really excited that

188

00:49:43.710 --> 00:49:51.000 Kristi Graves: all of our trainees have indicated that they've educated some community members about hereditary breast and ovarian cancer.

189

00:49:52.470 --> 00:50:00.540

Kristi Graves: Not quite two thirds have reported that they interacted with a healthcare professional about hereditary breast and ovarian cancer, about half

190

00:50:01.140 --> 00:50:08.070 Kristi Graves: thus far, had identified a patient or community member at high risk either one or more, and then

191

00:50:08.760 --> 00:50:27.660

Kristi Graves: 44% indicated that they've navigated at least one person or more to genetic services. We also have seen significant increases in knowledge and self efficacy or self confidence, as well as in genetic literacy between our baseline and the follow-up.

192

00:50:31.980 --> 00:50:50.130

Kristi Graves: And so, some of the lessons learned so far in our work, starting with the telegenetics and telephone genetic counseling, is that it appears to be quite viable option for reducing barriers to access of genetic counseling. I think we saw that,

193

00:50:51.270 --> 00:51:06.330

Kristi Graves: you know, over time, not only during Covid but also before covid I think telephone genetic counseling has been becoming much more common, and if there's any genetic counselors on the line I'd love to hear about their experiences with that.

00:51:08.010 --> 00:51:23.160

Kristi Graves: There remain some barriers related to access for genetic testing, and that includes accessing the ability to have the test itself, particularly if genetic counseling was delivered via telegenetics.

195

00:51:24.210 --> 00:51:33.690

Kristi Graves: We've considered a lot of different options, mailing saliva kits with videos of how to provide a quality saliva sample.

196

00:51:35.220 --> 00:51:52.980

Kristi Graves: In the telephone genetic counseling study kits were mailed to individuals and then they took it to a laboratory in their neighborhood or area in which there was a blood draw, so there was a you know the paperwork associated with how to do that.

197

00:51:54.150 --> 00:52:04.440

Kristi Graves: One thing we've considered and started doing is, for individuals who choose to have genetic testing, to have another appointment by video

198

00:52:05.580 --> 00:52:13.260

Kristi Graves: to then help guide them with the process of providing a sample and then how to get that sample in the mail and return it.

199

00:52:15.420 --> 00:52:26.970

Kristi Graves: And then in our more recent work, you know, a strong level of interest among individuals who are already working out in the community as community health educators or patient navigators.

200

00:52:27.540 --> 00:52:39.210

Kristi Graves: In terms of expanding their knowledge and skill sets to identify individuals who are at high risk for hereditary cancers. I think the model that we have for Árboles Familiares, although focused on

201

00:52:39.750 --> 00:52:45.960 Kristi Graves: hereditary breast and ovarian cancer, could easily be transportable to other hereditary cancer syndromes.

202

00:52:47.370 --> 00:52:55.440 Kristi Graves: And you know, right now, our workshop, we've delivered it virtually. Overall we're still in the process of

203

00:52:56.460 --> 00:53:03.270

Kristi Graves: we're just about to launch our six month follow up of our first virtual cohort so we'll see how they do in terms of their knowledge and

204 00:53:04.200 --> 00:53:20.310 Kristi Graves: improvements in genetic literacy and the like to see if it's comparable to in-person. For our population with individual serving the Latino Community, here does seem to be a interest in having in-person training to be able to connect with one another.

205

00:53:21.540 --> 00:53:26.100

Kristi Graves: And you'll see some of the pictures, here we have one of our case studies, as we have small teams

206

00:53:26.850 --> 00:53:44.790

Kristi Graves: go through a pedigree. So they draw the family, history and then they present a case to the group, we do candy DNA activities where they create double helix is out of candy during the Genetics 101 lecture and then the small group activities.

207

00:53:48.360 --> 00:53:54.960

Kristi Graves: So I'm again really honored to be here today, thank you so much for your time, I think I see something in the

208

00:53:55.350 --> 00:54:03.780

Kristi Graves: chat and very happy to have any questions or hear about your experiences related to telephone genetic counseling or

209

00:54:04.410 --> 00:54:21.210

Kristi Graves: working in the community to help raise awareness of genetic services. So I can and a big thank you, of course, to our team our trainees and then this is the team for Árboles project, so I can stop sharing now.

210

00:54:23.760 --> 00:54:26.490 Kristi Graves: And I do see that there's something in the chat.

211

00:54:29.580 --> 00:54:42.510 Kristi Graves: Oh yes, thank you. This was a question about the background country of origin and acculturation of the Latinx Community. So for our formative work we do have some of that information.

212

00:54:43.530 --> 00:54:50.910

Kristi Graves: I'm happy to share that and follow up and then I presented on some of the countries of origin of our trainees, as well.

213

00:54:52.440 --> 00:54:56.070

Kristi Graves: But happy to talk more about that question if there's more questions.

214

00:54:57.810 --> 00:55:08.040

Kim Kelly: Well, thank you so much, and I have a couple questions here to to kick off and maybe you can give us your impressions.

00:55:08.520 --> 00:55:22.110

Kim Kelly: But to begin, of what do you see as the primary challenge for genetic services in rural Appalachia? I know you don't routinely work there now, but maybe you have some ideas, based on your previous work.

216

00:55:22.650 --> 00:55:23.220 Kristi Graves: Sure.

217

00:55:24.300 --> 00:55:26.760 Kristi Graves: I you know I think some of the barriers are

218

00:55:28.020 --> 00:55:32.220 Kristi Graves: exportable to different communities so in rural Appalachia I think

219

00:55:33.990 --> 00:55:46.020

Kristi Graves: the number and location of genetic professionals specifically, genetic counselors, I think we need more genetic counselors overall in this country.

220 00:55:47.160 --> 00:55:52.890 Kristi Graves: And then, making sure that community based clinics

221

00:55:54.570 --> 00:56:03.150 Kristi Graves: have access, if not in house, then access to a genetic counselor ideally by something like telephone.

222

00:56:04.320 --> 00:56:14.880

Kristi Graves: So that individuals who are identified as having you know potential risk for hereditary cancer syndrome can be connected directly, without having to travel.

223

00:56:16.200 --> 00:56:29.580

Kristi Graves: And you know, ideally, from the comfort of their own home or from the clinic itself through telephone or through video, so I think number of genetic counselors is one barrier.

224

00:56:30.990 --> 00:56:39.090 Kristi Graves: And then, access to the testing options, I think that is changing with provision of buckle kits.

225

00:56:41.220 --> 00:56:43.740 Kristi Graves: And the opportunity to mail those in.

226 00:56:45.120 --> 00:56:55.260 Kristi Graves: You know I think a little bit about some of the direct to consumer testing and if people can do this for fun, then we should be able to do this for healthcare.

227

00:56:56.940 --> 00:57:01.350

Kristi Graves: So those are some of the barriers that I see. The other piece is

228

00:57:03.030 --> 00:57:21.000

Kristi Graves: you know conversations about cancer and conversations about risk factors and conversations about cancer in the family, and in some communities there may be taboos about talking about specific types of cancer or a strong family history.

229

00:57:22.440 --> 00:57:27.750

Kristi Graves: There could be also sense of well that's just how it is in our family without

230

00:57:29.400 --> 00:57:37.800

Kristi Graves: knowing that there could be information that might be of interest to some family members to indicate if they carry these genes that might be

231

00:57:38.220 --> 00:57:56.610

Kristi Graves: putting them at greater risk for having a hereditary cancer. So I think those are some of the pieces, awareness in the community, discussion of cancer in the family, lack of genetic counselors, and then logistic barriers to genetic testing, which includes costs or insurance as well.

232

00:57:58.950 --> 00:58:09.090

Kim Kelly: So, by the same token, what do you see as some potential opportunities, I mean you've talked a little bit about some of your work and maybe there will be some relation to that.

233 00:58:09.600 --> 00:58:11.670 Kristi Graves: Mhmm sure, so I think

234

00:58:12.780 --> 00:58:19.440

Kristi Graves: in rural communities, building on some of those community ties in the

235

00:58:19.470 --> 00:58:39.090

Kristi Graves: settings in which people are receiving some sort of healthcare, so that you know if there are individuals who could have start to have those conversations about cancer in the family or age at diagnosis, so those could be individuals at community clinics.

236 00:58:40.650 --> 00:58:43.320 Kristi Graves: Implementation of some

237 00:58:45.330 --> 00:59:02.310 Kristi Graves: family history taking in a systematic way and some of the clinics we've worked in, they do do that, but then there's sometimes a disconnect between what happens in terms of people are checking you know, I have a mother and a sister with cancer.

238

00:59:03.330 --> 00:59:25.560

Kristi Graves: It doesn't always then result in a referral to a genetic counselor, so I think that's starting to change but implementing some of the workflow systems to translate identification of red flags into a referral, I think, is one of the barriers that we need to overcome.

239

00:59:27.750 --> 00:59:31.140 Kim Kelly: Great. Thank you. Any other questions?

240

00:59:42.300 --> 00:59:53.340

Kim Kelly: So I think Marina was quite interested, but she had to leave, so I understand that this is lunch hour for some folks so

241

00:59:54.420 --> 01:00:12.210 Kim Kelly: appreciate that. Well, thank you for a wonderful talk Dr. Graves, and I enjoyed it learned, even though I'm familiar with your work, I learned a little bit more today, and it's got me thinking about some of the opportunities there, and certainly

242

01:00:14.070 --> 01:00:28.200

Kim Kelly: previously, in our sessions, the idea of kind of information leads and that decision aids has been discussed, so I think there is a fair bit of interest in that among the group and

243

01:00:28.920 --> 01:00:34.560 Kim Kelly: you know some of the folks that had mentioned some interest haven't been here, but hopefully they'll hear this.

244 01:00:36.570 --> 01:00:39.390 Kim Kelly: They'll hear this on the recording.

245

01:00:41.100 --> 01:00:48.990 Kim Kelly: And there's a follow up from Dr. Galves, so and she is interested in pharmacogenomics.

246 01:00:49.290 --> 01:00:49.920 Kristi Graves: Oh great.

247 01:00:50.580 --> 01:00:51.030 Kim Kelly: Um

248 01:00:51.420 --> 01:00:57.870 Kristi Graves: I'll put my email in the chat and if anyone has thinks of other questions later, you know, please feel free to reach out to me and

249

01:01:00.150 --> 01:01:13.830

Kristi Graves: you know I think there's a lot that we can do out in our communities to raise awareness about hereditary cancer and genetic services, so I applaud each of you for doing the work that you're doing and for your interest.

250

01:01:14.850 --> 01:01:28.620

Kim Kelly: Well, thanks so much for your talk today, and we have our evaluation survey link posted in the chat and we appreciate folks giving us feedback and

251

01:01:29.220 --> 01:01:37.800

Kim Kelly: that certainly helps with our funder and to let them know if this is the kind of thing that we need to work on and I

252

01:01:38.220 --> 01:01:50.160

Kim Kelly: am hearing a lot of discussion in different groups about trying to address this issue. So next month, I will be presenting on some of the data

253

01:01:50.790 --> 01:02:00.630

Kim Kelly: from our session, kind of as a wrap-up and appreciate anyone that can come and contribute and discuss how

254

01:02:01.080 --> 01:02:09.480 Kim Kelly: we might plan to move forward, but we've got a lot of great ideas, both from the initial intake whenever people registered

255

01:02:09.900 --> 01:02:24.060

Kim Kelly: for the sessions, as well as during each of our speakers and ways that we might approach, so again, thank you all so much, and if there are no questions, then I'll just thank you again, Dr. Graves and look forward to seeing you next month.

256

01:02:25.590 --> 01:02:30.480 Kristi Graves: Thank you so much for having me and thanks for organizing this great series.

257

01:02:34.320 --> 01:02:35.610 Kristi Graves: Hope everybody has a good day.